Clinical application of pharmacogenetics in gastrointestinal diseases

被引:6
作者
Saito, Yuri A. [1 ]
Camilleri, Michael [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Clin Enter Neurosci Translat & Epidemiol Res, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
关键词
drug metabolism; drug toxicity; pharmacogenetics; pharmacogenomics; polymorphisms;
D O I
10.1517/14656566.7.14.1857
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As knowledge of the human genome grows, there will be a direct impact on the management of specific diseases. Within gastroenterology and hepatology, there has been a change in the understanding of how variations or mutations in genes involved in drug metabolism or disease pathophysiology affect response to therapy. This review discusses the application of clinical. pharmacogenetics to the following diseases and disorders: inflammatory bowel disease, Helicobacter pylori infections, gastroesophageal reflux disease, irritable bowel syndrome, functional dyspepsia, liver transplantation and colon cancer. Although only a few genotyping tests are regularly used in clinical practice, it is anticipated that studies will propel the routine use of many of the tests described in this review, in the future.
引用
收藏
页码:1857 / 1869
页数:13
相关论文
共 107 条
[1]   Review Article: The genetics of inflammatory bowel disease [J].
Ahmad, T ;
Satsangi, J ;
Mcgovern, D ;
Bunce, M ;
Jewell, DP .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (06) :731-748
[2]   ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression [J].
Allorge, D ;
Hamdan, R ;
Broly, F ;
Libersa, C ;
Colombel, JF .
GUT, 2005, 54 (04) :565-565
[3]   Increased transcriptional activity of the CYP3A4* 1B promoter variant [J].
Amirimani, B ;
Ning, B ;
Deitz, AC ;
Weber, BL ;
Kadlubar, FF ;
Rebbeck, TR .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2003, 42 (04) :299-305
[4]  
Ando Y, 2000, CANCER RES, V60, P6921
[5]   Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients [J].
Anglicheau, D ;
Verstuyft, CL ;
Laurent-Puig, P ;
Becquemont, L ;
Schlageter, MH ;
Cassinat, B ;
Beaune, P ;
Legendre, C ;
Thervet, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1889-1896
[6]  
AZATHIOPRINE, 2006, PHYS DESK REFERENCE, V129
[7]   Identification and functional characterization of new potentially defective alleles of human CYP2C19 [J].
Blaisdell, J ;
Mohrenweiser, H ;
Jackson, J ;
Ferguson, S ;
Coulter, S ;
Chanas, B ;
Xi, T ;
Ghanayem, B ;
Goldstein, JA .
PHARMACOGENETICS, 2002, 12 (09) :703-711
[8]   MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients [J].
Bonhomme-Faivre, L ;
Devocelle, A ;
Saliba, F ;
Chatled, S ;
Maccario, J ;
Farinotti, R ;
Picard, V .
TRANSPLANTATION, 2004, 78 (01) :21-25
[9]   ABC of colorectal cancer - Epidemiology [J].
Boyle, P ;
Langman, JS .
BRITISH MEDICAL JOURNAL, 2000, 321 (7264) :805-808
[10]  
CAMILLERI CE, 2006, IN PRESS AM J GASTRO